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1. Introduction 
The two main issues that concern glaucoma patients before and after penetrating 
keratoplasty and posterior lamellar procedures and patients that develop glaucoma after 
surgery are the risks of graft failure and the aggravation of the glaucoma. Failure of the 
corneal graft may require regrafting, which increases the risk of developing or aggravating 
glaucoma, while uncontrolled glaucoma may result in graft failure and further damage to 
the optic disc and visual field. These two problems may lead to each other creating a vicious 
circle. They should be treated by glaucoma and corneal specialists or by someone who is 
expert with both.  
Glaucoma was found in 10-42% of the patients with a single corneal transplantation, 0-27% 
of them had preoperative glaucoma.1-6 Preexisting glaucoma was usually a result of an 
initial insult such as chemical burn or secondary glaucoma. In repeated corneal 
transplantation, the incidence of postoperative glaucoma was higher (14-47%) than in 
primary transplantation.7-12 It increases with increased number of regrafts and in aphakia. 
Corneal graft failure 3 years after keratoplasty occurred in 29-47% when glaucoma was 
present, compared with 9-30% when it was absent.13,14  
Patients requiring penetrating keratoplasty and lamellar procedures (deep lamellar 
keratoplasty, Descemet's stripping (automated) endothelial keratoplasty, Descemet’s 
membrane endothelial keratoplasty) may suffer from preexisting various types of open 
and closed angle glaucomas, which may be primary or secondary. Primary open angle 
and primary closed angle glaucomas may preexist and corneal surgery may be required 
for unrelated disorders such as Fuchs’ corneal dystrophy. Secondary glaucomas may 
occur due to open and closed globe injuries. In those injuries, the glaucoma may be of 
open angle and caused by obstruction of the trabecular meshwork by red blood cells 
(from hyphema), ghost cells (ghost cell glaucoma) or tearing of the meshwork (angle 
recession). It may also be closed-angle caused by peripheral anterior synechiae. Corneal 
transplantation may also be required in chemical burns especially alkali. In these cases, 
the cornea may be opaque because of chronic edema and scarring. Secondary glaucoma 
may also be associated with corneal abnormalities such as anterior mesenchymal 
dysgenesis (e.g., Peter’s and Axenfeld-Rieger’s anomalies). In these disorders, in addition 
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to corneal opacity due to scarring, the angle may be poorly formed. The common features 
for all these conditions are persistent corneal edema and scarring due to endothelial 
decompensation. The decompensation is a result of a combination of damaged or 
compromised endothelium (whether by trauma or other corneal disorders) and increased 
intraocular pressure (IOP) that contributes to egress of aqueous humor into the corneal 
layers. Corneal opacity due to persistent edema and scarring is more common in these 
conditions than in normal population. 
Repeated or even primary corneal transplantation may also result in secondary glaucoma. 
The attributing factors for secondary glaucoma include 1. Donors button undersizing, 
which results in corneal graft over-stretching, causing corneal flattening and angle 
closure. 2. Trauma to the angle by the inadvertent touch by surgical instruments. The 
damage might be micro or macroscopic. 3. Corticosteroid-induced glaucoma, since topical 
and sometimes systemic corticosteroids are being frequently use after transplantation to 
decrease the risk for corneal graft rejection or to treat it. 4. Posterior synechiae that may 
develop due to postoperative intraocular inflammation especially if the angle is 
traumatized or becomes shallow. The most common forms of post-keratoplasty glaucoma 
in single and repeated corneal transplantation are chronic angle closure followed by 
steroid-induced glaucoma.  
2. Assessment of patients requiring penetrating keratoplasty 
The preoperative office evaluation of patients requiring penetrating keratoplasty or lamellar 
procedure whether or not having glaucoma includes defining the primary indication for 
surgery. Certain indications may require certain precautions or additional treatment to 
prevent loss of the graft clarity. For example, corneal transplantation for infectious diseases 
such as herpetic, fungal or acanthamebic keratitis require prolonged postoperative anti-
herpetic, fungal or acanthamebic treatment to prevent reactivation. Defining the associated 
ocular disorders of the recipient and donor is paramount.12 Corneal vascularization 
increases the risk of corneal graft rejection especially if involves three or more quadrants 
and requires prolonged use of corticosteroids as well as immuno-suppressants. Ocular 
surface disorders such as entropion and trichiasis also increase the likelihood of graft loss 
due to persistent rubbing of the ocular surface that results in corneal epithelial defects and 
ulcers that may lead to perforation.15 Limbal cell deficiency in corneal cicatricial disorders 
such as ocular cicatricial pemphigoid and erythema multiforme (Steven Johnson disease) 
provides poor supporting environment to the graft, while dry eyes do both (poor 
supporting and increased friction upon blinking).  Poor blinking and lagophthalmos may 
also cause dryness of the ocular surface resulting in persistent epithelial defects, ulcers and 
even perforation. These findings should be pretreated.  
Cataract, glaucoma and retinal disorders may be associated with poor visual prognosis 
despite of clear corneal graft and should be evaluated before any corneal procedure. 
Defining the associated systemic disorders in recipient and donor are also essential. 
Diabetes mellitus is also manifested as fragile epithelium and slow epithelial healing, which 
could endanger the corneal graft. 
Before any corneal surgery, best-corrected visual acuity of each eye should be obtained and 
recorded. This will assist in surgery decision making. Ultrasound is part of the evaluation if 
the cornea is severely opaque and fundus cannot be evaluated. It is used to rule out retinal 
detachment and intraocular masses (e.g., choroidal melanoma). When ocular disorders other 
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than corneal disease exist, such as glaucoma and retinal disorders, they should be evaluated 
for their contribution to visual acuity. The evaluation includes potential acuity meter (PAM), 
Lambda and laser interferometry. With these instruments, if the visual acuity is improved, 
the eye has a potential for visual recovery and a corneal surgery should be attempted. In 
non-verbal patients as children or in patients with mental retardation, a less accurate 
method to evaluate the potential for visual recovery is electroretinography (ERG). When 
anamnesis cannot be obtained, poor prognostic factors for visual improvement are 
nystagmus, which develops in the first 3 postnatal months, and esotropia that develop in the 
first 6 postnatal months and indicate severe irreversible amblyopia. Exotropia on the other 
hand may be acquired at older age and therefore, with poor anamnesis is not a poor 
prognostic factor for visual recovery. 
The preoperative evaluation should include a complete ocular examination including 
examining the anterior chamber angle, especially following ocular trauma, burns, 
preexisting glaucoma and candidates for large diameter grafts. If the cornea is opaque, 
ultrasound biomicroscopy (UBM) is a good alternative for gonioscopy. In presence of 
shallow anterior chamber, peripheral anterior synechiae or partially closed angle even with 
normal IOP, placement of anterior chamber IOL is contraindicated in triple procedures, 
because it may result in the development of secondary glaucoma. 
3. Preoperative tips 
Consider alternative treatment options for penetrating keratoplasty, especially if glaucoma 
exists. If the corneal opacity is central and localized (e.g., in Peter's anomaly), optical 
iridectomy may be a better surgical alternative. Rotational autokeratoplasty is an alternative 
for eccentric. If the corneal opacity is minimal, surgery may not be warranted. It is always 
imperative to consider whether the expected visual acuity will be better than the 
preoperative visual acuity. If not, it is better to avoid surgery. 
It is important to perform complicated surgical procedures such as filtration surgery in 
uncontrolled and controlled glaucoma patients before corneal transplantation or posterior 
lamellar procedures. The IOP should be controlled at time of the penetrating keratoplasty or 
posterior lamellar procedures. Otherwise, the graft may become edematous and lost. In 
patients with glaucoma, any procedure should spare the limbus and conjunctiva as much as 
possible to allow glaucoma filtration surgery.  
4. Surgical steps of penetrating keratoplasty to increase the success rate 
Oversized donor corneal button is always required to decrease the risk for development of 
secondary glaucoma and aggravating a preexisting one. The details for oversizing are 
described below. 
Specular microscopy of the donor button to ensure an endothelial cell count of more than 
2,000 mm2 without endothelial polymegatism or pleomorphism will at least guarantee that 
the corneal graft has safety margins and that the risk of endothelial decompensation will be 
decreased. 
Pretreatment of preexisting glaucoma is a crucial step in successful penetrating and 
posterior lamellar procedures. Therefore, it is important recognizing the type and the 
etiology of preexisting glaucoma. Surgical pretreatment should be considered even in 
medically controlled glaucoma, because these patients may become uncontrolled after 
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surgery and this may endanger the transparency of the corneal graft. Trabeculectomy is the 
treatment of choice for primary open angle glaucoma. Antimetabolites such as mitomycin-C 
(MMC) are indicated for all patients under the age of 55 even in primary surgery, for 
repeated surgery and for combined procedures. Trabeculectomy should be preferred over 
glaucoma drainage devices in triple procedures and in the presence of corneal graft. MMC 
should be applied in all cases of secondary glaucomas, triple procedure or in the presence of 
corneal graft although potential diffusion of the drug may endanger the endothelium. MMC 
0.04% is soaked by a small piece of sponge and is placed under the scleral flap before 
penetrating into the anterior chamber or under the conjunctival flap for 2min avoiding its 
edges. It should not be placed over corneal button–recipient bed interface. Such a low 
concentration and short exposure minimize the risks for complications such as poor healing, 
scleral melting, anterior chamber reaction and increased IOP. 
In angle closure glaucoma, laser iridotomy and laser iridoplasty or synechiolysis are 
warranted. Laser iridotomy may facilitate aqueous flow from the posterior into the anterior 
chamber and deepen the anterior chamber. Laser iridoplasty causes shrinkage of the 
peripheral iris and retracts the base of the iris to open the angle, while, synechiolysis has a 
similar effect by breaking peripheral anterior synechiae and opening the angle. The last two 
procedures are beneficial if peripheral anterior synechiae have been present for less than 6 
months. Peripheral iridectomy may replace laser iridotomy only if iridotomy cannot be 
performed due to corneal opacity, thick iris or when laser in unavailable. The procedures are 
described below. 
Penetrating keratoplasty should be delayed until the intraocular inflammation subsides and 
the IOP is stable within the target pressure range. This should be at least 3 months after any 
intraocular surgery. 
5. Prevention of secondary glaucoma 
Several precautions should be employed to prevent a secondary glaucoma. As mentioned, 
preoperative evaluation of the anterior chamber angle is essential especially in patients with 
preexisting glaucoma. If the angle is already compromised (close, narrow or has peripheral 
anterior synechiae), the risks of development of glaucoma or aggravation of preexisting one 
increase.  It is important to oversize corneal donor button by 0.5-0.75 mm. In keratoconus or 
keratoglobus, an over-sizing of 0.25 mm is sufficient to decrease the risk of postoperative 
angle closure, while preventing too steep postoperative graft. For large graft diameter (8.0-
9.5 mm) that is required sometimes for corneal perforations, large descematocele or 
widespread disease, an over-sizing of 0.75-1.0 mm is advocated. Avoiding manipulations 
near the angle with surgical instruments is important. The only exception is when 
synechiolysis is performed. The angle may also be filled with viscoelastic agent to protect it 
during the procedure, but the viscoelastic material should be aspirated at the conclusion of 
the surgery to prevent postoperative high IOP. To decrease damage to the trabecular 
meshwork, preoperative and postoperative intraocular inflammation should be controlled. 
This may be done by topical corticosteroids with high corneal penetrance such as 
prednisolone acetate (Pred Forte®). The frequency of drop instillation depends on the degree 
of inflammation and it is tapered gradually according to the response. Additional systemic 
corticosteroids may be employed for severe or recurrent sterile uveitis. Usually, 1 
gr/kg/day of prednisone is sufficient. 
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6. Post-keratoplasty glaucoma 
If glaucoma develops after corneal surgery, a distinction between immediate postoperative 
and late postoperative glaucoma should be made. Immediate postoperative glaucoma 
develops within a week after surgery in 42-55% of the primary keratoplasties. The causes for 
its development include viscoelastic agent left in the anterior chamber and blocking the 
drainage of the aqueous humor through the angle and corticosteroid-induced glaucoma. 
The later develops after the initiation of corticosteroid treatment and occurs at least in 20-
30% of the patients. It can occur with any form of corticosteroid although it occurs more 
often after topical use. The increase in IOP in these cases is usually reversible if diagnosed 
early and if corticosteroids are discontinued. Therefore, topical and if necessary systemic 
corticosteroids should be replaced immediately with non-steroidal anti-inflammatory 
(NSAID) medications. Corticosteroid-induced glaucoma may be avoided by employment of 
topical NSAID such as ketorolac tromethamine 0.5% (Acular® or Tradol®), diclofenac 
sodium (Voltaren® (0.1%), Solaraze® (3%)) or indomethacin 1% (Indoptic®). Its incidence is 
also lowered with IOP sparing corticosteroids such as loteprednol etabonate 0.5% 
(Lotemax®) or rimexolone 1% (Vexol®) but because of their low potency, they may be more 
frequently required.  
Late postoperative glaucoma may develop weeks or months after surgery. The incidence of 
this complication is 10-42% after primary keratoplasty. The risk factors for its development 
include preexisting glaucoma in 27-80% of the cases, aphakia in 20-39%, semi-flexible, 
closed-loop anterior chamber IOL in 23-50%, regrafting in 43% and wound dehiscence in 
50%. Anterior mesenchymal disorders are risk factors for glaucoma in 50-90% of the 
patients, while open or closed globe injury in 31-77%. Glaucoma may be encountered in up 
to 47% of the patients with pseudophakic or aphakic bullous keratopathy, and the corneal 
edema may be a result of it. Certain old types of IOLs have also been associated with late 
postoperative glaucoma including iris-fixed anterior chamber IOL due to uveitis-glaucoma-
hyphema (UGH) syndrome, caused by rubbing of the IOL against the iris. Large corneal 
grafts and posterior lamellar grafts may also increase the risk for glaucoma development 
because they may interfere with the angle. The same may occur from the sutures if they are 
long, tight and full thickness The causes for late postoperative glaucoma include synechial 
angle closure, changes in angle ultrastructure, direct mechanical damage to angle by 
surgical instruments, chronic postoperative inflammation causing toxic effects and presence 
of vitreous in the angle. Immune graft rejection was found to be more common in patients 
developing postoperative glaucoma than in those who did not develop it.16,17 The glaucoma 
also increases with the number of corneal transplantation procedures.17 
7. Post-keratoplasty evaluation of preexisting and secondary glaucoma 
The evaluation of the anterior chamber is important not only before corneal 
transplantation and other posterior lamellar procedures but also after surgery, because if 
there is a progressive closure of the angle or formation of peripheral anterior synechiae, 
they may be treated before the development of glaucoma or to prevent its worsening. 
Periodic gonioscopy for development of anterior chamber angle closure is performed with 
gonioscopic lens when the peripheral cornea is clear. A 4 mirror hand-held lens has the 
advantages of avoiding viscoelastic material and of short diameter that allow indentation 
of the cornea. This allows distinguishing between apposition of the iris against the angle 
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and true closure. It also allows breaking of fresh anterior synechiae if present. Indentation 
should be performed cautiously immediately after surgery, because it can result in wound 
dehiscence. Other gonioscopic lenses include the Goldman three and four mirror lenses, 
which have a broader base (diameter) and cannot indent only the cornea. They also 
require viscoelastic agent. Newer imaging modalities of the anterior chamber angle 
include the anterior segment optical coherence tomography (OCT) using 1310nm 
wavelength, which has a resolution of 10µm and Scheimpflug camera (Pentacam®) that 
has UV-free blue light source of 475nm with a similar resolution. Scheimpflug camera 
requires a clear cornea and direct visualization of the angle is still a better choice. When 
the peripheral cornea is opaque, ultrasound biomicroscopy (UBM) is the imaging of 
choice. It may also assists in evaluation of the ciliary body for congestion as part of uveal 
effusion syndrome and for aqueous misdirection. Thus, it may elucidate the mechanism of 
closed angle glaucomas. 
Periodic IOP measurements are essential to disclose the development of glaucoma or 
aggravation of preexisting one. They should be performed in scheduled meetings during 
different hours of the day to reveal high IOP spikes in patients with high diurnal variations. 
In cases of doubt, a diurnal IOP curve is indicated and is usually performed every 4 hours 
between 8:00 and 20:00, but may be performed more frequently (i.e., every 2 hours) and 
during nighttime as well. IOP measurements should be especially performed when a patient 
is treated with topical and/or systemic corticosteroids or receives corticosteroid in other 
forms (e.g., inhalations). If newly IOP elevation is disclosed, recognizing the type of 
secondary glaucoma is important in treatment decision making (see above). IOP 
measurements of with Goldmann applanation tonometry may be challenging, because of 
corneal graft edema, which underestimate the real IOP and corneal graft astigmatism that 
distorts the image. When measured with Goldmann, the prism may be rotated to aim the 
red mark on it to the least curved corneal meridian (the negative axis). To overcome the 
astigmatism, the IOP may be measured twice, one in 90 degrees from the other, and the 
mean IOP may be calculated from these two measurements. IOP measurements may be 
performed by pneumatic tonometer, Tono-Pen or Mackay-Marg tonometer if they are 
impossible to be obtained with Goldmann. Alternatively, the IOP may be qualitatively 
estimated with a glass rod or by digital palpation. In eyes with corneal scarring, the IOP is 
overestimated.  
When the diagnosis of postoperative or secondary glaucoma is established and the patient is 
being treated, it is important to avoid discontinuation of the anti-glaucoma medications, 
unless the patient is closely being followed-up. The course of postoperative glaucoma may 
be unpredictable and unstable. There might be high long-term fluctuations; i.e. cycles of 
normal IOP may alternate with increased IOP and the ophthalmologist may mislead to 
think that the glaucoma has resolved.  
Actually, when a diagnosis of secondary glaucoma is made, the patient should always be on 
anti-glaucoma medications, unless he/ she develops excessive low IOP or intermittent 
ocular hypotony. In such cases, the anti-glaucoma medications should be discontinued 
while the patient is followed- up closely. These cases may represent a transition to phthisis 
bulbi. In cases of ocular hypotony, corticosteroids either topically or systemically may 
induce some IOP elevation, but if this does not result, pars plana vitrectomy with silicone oil 
injection into the vitreous might prevent phthisis. Pars plana vitrectomy with silicone oil 
injection is indicated for chronic ocular hypotony even if the visual acuity is no light 
perception, because it may prevent phthisis bulbi. 
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8. Treatment of progressive angle closure 
The treatment of postoperative progressive angle closure even with normal IOP includes 
peripheral laser iridotomy and topical corticosteroids to control anterior chamber 
inflammation. If the IOP increases, a prompt surgical synechiolysis is warranted. 
9. Treatment of secondary glaucoma 
Open angle glaucoma is treated in the following order. The first line of treatment is medical 
with alpha-agonists (brimonidine tartrate) and beta-blockers (timolol maleate, betaxolol). In 
phakic eyes, prostaglandin analogs (latanoprost) and adrenergic agents (dipivefrin, 
epinephrine) may be added. In aphakic and pseudophakic eyes, prostaglandin analogs and 
adrenergic agents may induce cystoid macular edema (CME), which may result in a 
decrease in visual acuity, and therefore should be avoided. Topical carbonic anhydrase 
inhibitors (dorzolamide, brinzolamide) may cause graft failure due to toxicity to endothelial 
cells. Miotics may initiate intraocular inflammation by breaking the blood-aqueous barrier 
and may increase the likelihood of corneal graft rejection. In aphakic eyes, the risk of retinal 
detachment also increases. Therefore, these agents should be spared if possible. 
The adverse effects of beta-blockers include superficial punctate keratopathy, corneal 
anesthesia and dry eyes. Alpha-adrenergic agents may also cause superficial punctate 
keratopathy and dry eyes. 
If medical treatment fails, trabeculectomy with MMC (option for two such procedures) 
should be considered (Figure 1). However, some authors suggested that the prognosis might 
be poorer than for placement of a glaucoma drainage implant. If a trabeculectomy is 
performed, a soaked sponge (WekCel) of MMC 0.2-0.4 mg/ml under the scleral flap before 
penetrating the anterior chamber (or under the conjunctiva avoiding its edge) for 2-3 min 
should be added. The MMC should not be placed over corneal button–recipient bed 
interface. Then the area should be copiously irrigated with balanced salt solution or saline. 
This procedure may be repeated if it failed once. In some cases, the filtration procedure may 
be functioning well causing a decrease in IOP, but to insufficient level (above the target 
pressure). In such a case, an additional trabeculectomy rather than anti-glaucoma medications 
may be successful decreasing further the IOP to the desired level because they may diminish 
the filtration through the trabeculectomy resulting in its failure for long term. Also, with a 
successful second trabeculectomy, the patient may not need long-term topical medications, 
which are a burden. An alternative for MMC is 5-fluorouracil (5FU). Five-mg may be 
injected subconjunctivally before or at intervals after surgery, but is less potent. Another 
option is to place 50mg/ml of 5-FU over or under the scleral flap intraoperatively. It inhibits 
epithelial proliferation, while MMC is better against fibrous proliferation. Both drugs may 
be injected in conjunction. 
The complications of trabeculectomy with MMC in the presence of corneal graft are similar 
to those without a graft, but in addition, damage to the endothelium may be caused by the 
MMC, if it penetrates into anterior chamber. The same precautions that apply for placing 
MMC during surgery for primary open angle glaucoma should be applied here.   
If one or two trabeculectomies with MMC have been failed or as a first surgical option, 
glaucoma shunt tube may be performed. Anterior or posterior drainage devices are 
available. Anterior drainage devices connect the anterior chamber with the subconjunctival 
space. Schlemm's canal or suprachoroidal space are easier to implant and require only 
limited healthy conjunctiva to function. Among the anterior drainage devices are Ex-Press, 
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Solx Gold shunt and iStent. Posterior drainage devices also drain the anterior chamber 
through a silastic tube, but the tube is connected to a plate that is placed under the 
conjunctiva posteriorly. This is the reason that they are called posterior devices. Two types 
of posterior shunt tubes exist. The first type is with control of the flow (with a “valve” or 
flow resistance) includes Ahmed (New World Medical, Rancho Cucamonga, CA) and 
Krupin-Denver (Hood Laboratories, Pembroke, MA) drainage implants. The second type is 
without pressure control and includes Molteno single or double plate (IOP, Inc., Costa Mesa, 
CA, USA, and Molteno Ophthalmic Limited, Dunedin, New Zealand), Baerveldt (Advanced 
Medical Optics, Santa Ana, California, USA), Shocket (self-assembled) and Eagle Vision 
(Eagle Vision, Inc. Memphis, TN, USA) implants. The later require blocking the aqueous 
flow for a few days externally by temporary suture or internally by passing a suture through 
the lumen of the tube or injecting viscoelastic agent. The implantation may also be 
performed as a two-stage implantation, to decrease the risk for postoperative hypotony. 
Ahmed and Krupin implants should be preferred over the implants without a valve, 
because the risk for postoperative overflow and hypotony that may result in endothelial-iris 
and lens touch is decreased. Ahmed has a convenient plate to implant and suture in variable 
sizes including for pediatric population. 
 
 
Fig. 1. Trabeculectomy in presence of clear corneal graft in a pseudophakic eye. Note the 
two patent peripheral iridectomies 
The experience with anterior drainage devises is limited to a short follow-up, since they are 
relatively new. Results with Ex-press are promising.18 The success rate defined as IOP below 
21mmHG in 15 corneal transplanted eyes with closed angle glaucoma was 87% over a mean 
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follow-up of 12 months, but a longer follow-up is required. The implantation is performed 
under 5x5mm partial thickness scleral flap similar to limbal-based trabeculectomy and 
MMC 0.05% is applied for 3min and rinsed after it. No data exist yet concerning the other 
anterior devices. In cases of corneal transplantation or posterior lamellar procedure, the 
position of the shunt tube may play a critical role in preservation of clear graft. In phakic 
eyes, the tube is usually placed through the anterior chamber angle. This results in control of 
the glaucoma in 68-96%.19-25 However, placement of the tube into the anterior chamber may 
endanger the transparency of the graft due to tube-endothelial touch or turbulent flow of 
aqueous through the tip even in the absence of touch. Additional causes include eye rubbing 
and pressure on the cornea on sleeping. This complication is unique for corneal grafts and 
for compromised corneas (e.g., in Fuchs’ endothelial dystrophy), since it has been 
demonstrated that progressive endothelial cell lost is observed after placement of glaucoma 
drainage tube into the anterior chamber angle, and this may occur even in the absence of 
endothelial-tube touch. Forty-two percent of the eyes with corneal transplants develop 
corneal decompensation.23 
It is possible to redirect the tube placed into the anterior chamber angle through an existing 
iridectomy to the posterior chamber in aphakic or pseudophakic eyes as long as the iris 
would not block it. Another alternative in pseudophakic or aphakic eyes, is to place the tube 
into the posterior chamber through the ciliary sulcus, by an incision made 1mm posterior to 
the limbus.26 This procedure is especially advantageous in eyes with corneal transplants or 
which are candidates for corneal transplantation or posterior lamellar grafts, Fuchs’ corneal 
dystrophy, shallow anterior chamber and extensive synechial angle closure. A meticulous 
anterior vitrectomy is required if cases of vitreous loss. 
For placement of glaucoma shunt tube into the ciliary sulcus, limbal peritomy is performed 
in the upper temporal (or if not feasible, inferonasal) quadrant and dissection is carried 
posteriorly over the sclera. The drainage plate is secured to the sclera with 6-0 polyester 
sutures 8 to 10mm posterior to the limbus between the superior and the horizontal recti 
muscles. A 2 to 5mm-long scleral tunnel is fashioned with angled crescent knife and the 
drainage tube is passed beneath it. Alternatively, the tube may be covered with scleral, 
corneal, pericardial or dural patch adjacent to the external sclerostomy. The tube is passed 
into the ciliary sulcus through a sclerostomy performed 1mm posterior to the limbus at 11 or 
1 o’clock position under a half-thickness, limbal based scleral flap of 3x3mm. The sclerostomy 
is performed with a myringotomy blade that is inserted with its shaft perpendicular to the 
limbus and beveled parallel to the iris plane (as performed for scleral-fixated intraocular 
lens). The position of the tip of the blade is observed through the dilated pupil to confirm its 
position and avoid ciliary body separation. The edge of the tube is protruding 3mm into the 
posterior chamber. It should not exceed the dilated pupil margin to avoid glare and should 
not be too short to avoid blockage by ciliary processes. The fornix-based conjunctival flap is 
secured to the limbus with 7-0 polygalactin sutures (Figures 2,3). At the conclusion of the 
surgery betamethasone acetate 3mg and gentamicin sulfate 20mg are injected 
subconjunctivally 180° away from the implant plate. Topical corticosteroid, antibiotic and 
cycloplegic are prescribed and tapered gradually. The main potential complications include 
ciliary body separation and suprachoroidal hemorrhage. These were not observed in a series 
of patients that underwent this procedure.26-28 The corneal grafts remained clear for years of 
follow-up and the glaucoma was controlled following this procedure. Placement of the 
shunt tube into the posterior chamber through the ciliary sulcus is contraindicated in phakic 
eyes because it may endanger the integrity of the crystalline lens. 
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Fig. 2. A diagram showing a side view of placement of a glaucoma drainage device in the 
ciliary sulcus. c – cornea, a/c – anterior chamber, I – iris, p – pupil, s/f – scleral flap,  c/b – 
ciliary body, s/t in c/s – shunt tube in the ciliary sulcus, s/t in sl/tl – shunt tube in scleral 
tunnel, d/i – implant disc 
 
 
Fig. 3. The tip of ciliary sulcus glaucoma shunt tube behind the iris during surgery before 
placing a corneal graft 
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In cases of posterior segment disorders, when pars plana vitrectomy is required, the tube 
may be placed into the vitreous cavity through it.30,31 A meticulous vitrectomy is a 
prerequisite so vitreous strands will not block the tube. The common feature for 
placement of the shunt tube into the posterior chamber through the ciliary sulcus or into 
the vitreous cavity through the pars plana is placing the tip of the tube away from the 
corneal graft, which decreases the risk of endothelial cell loss and corneal graft 
decompensation.  
For pars plana placement of glaucoma drainage device, a limbal peritomy is performed and 
the lateral and superior rectus muscles are engaged by 4-0 silk traction sutures. The sclera is 
exposed further back by elevating the conjunctiva and Tenon’s capsule with blunt dissection. 
The plate is secured to the superotemporal sclera with 6-0 polyester sutures. Then a three-
port pars plana vitrectomy is performed through sclerostomies 3.5mm from the limbus. The 
tube is introduced 5mm into the vitreous through the superotemporal sclerostomy. A sclera, 
corneal, dural or pericardial patch may be used to cover the tube and the conjunctival-Tenon 
flap is sutured to the limbus with 7-0 polygalactin sutures. A Pars Plana Clip (Model 
PC,New World M, Inc., Rancho Cucamonga, CA, USA), which can be used with any 
drainage device, or Hoffman elbow, which is mounted on a Baerveldt 350-mm2 implant 
(Advanced Medical Optics, Inc., Santa Ana, CA, USA) may be used. New pars plana Ahmed 
and Baeverdlt implants are also available and the procedure may be performed using even 
the regular glaucoma setones, preferably those with a “valve”. Fluid-gas exchange provides 
a temporary tamponade and prevents postoperative hypotony. Pars plana vitrectomy and 
placement of glaucoma shunt device may be performed endoscopically in eyes with media 
opacity such as corneal opacity.32 This procedure allows controlling the glaucoma first and 
then performing corneal surgery later to improve visual acuity. Possible unique complications 
for this procedure include vitreous hemorrhage, retinal detachment and choroidal 
detachment. Although corneal graft failure is reduced if the glaucoma drainage device is 
placed through the ciliary sulcus or pars plana and if the glaucoma is controlled, it should 
be remembered that there are other causes that may result in graft failure. 
In posterior lamellar grafts, if a glaucoma shunt tube is introduced into the anterior 
chamber, the graft may block the tip of the tube resulting in increased IOP. It can be avoided 
by trimming the tip of the tube, so it will not be blocked. It is also possible to pre-plane the 
corneal surgery and to prepare a thin lamellar graft or perform a DMEK rather than DSAEK 
(Figures 4,5).29 Tube-endothelial touch without blockage may also occur and is manifested 
as corneal edema. It may increase the risk for corneal graft rejection. If tube-endothelial 
touch or tube blockage is suspected, the diagnosis may be confirmed by direct visualization 
with slit lamp biomicroscopy or indirectly with UBM, Scheimpflug camera (Pentacam) or 
anterior segment OCT. When tube-endothelial touch or tube blockage is confirmed, the tube 
should be trimmed. The trimming should be performed so that the opening of the tip would 
not face the corneal graft, because turbulence at the tip may cause progressive loss of 
endothelial cells and corneal decompensation that will require a new transplant. The 
opening should not face the iris as well because it may be blocked. The tip may also be 
redirected if long and mobile enough. This can be done by retrieving the tube from the 
anterior chamber, creating a new passage into the chamber and suturing the old route. Just 
moving the tube in the existing route is usually unhelpful. If the graft is edematous at the 
time of managing the tube, regrafting may be performed later when the IOP is stable and 
the eye is quiet, if the edema has not been resolved. 
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Fig. 4. Glaucoma shunt tube (arrow) in an eye after Descemet’s membrane - endothelial 
keratoplasty (DMEK). Note the clear lamellar graft 
 
 
Fig. 5. Pentacam image of the same eye as in figure 4 showing the position of the tube in the 
anterior chamber (arrow) 
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Laser procedures for the angle such as selective trabeculoplasty have a limited value in the 
long-term treatment of secondary open angle glaucomas and therefore, were not included in 
the sequence of treatment. The main reason is their limited effect in this type of glaucoma. 
Even in primary open angle glaucoma, where it is more effective, the success rate is only 
50% 5 years after the procedure. 
10. Closed angle glaucoma 
Closed angle glaucoma should be confirmed by gonioscopy or UBM or with other imaging 
techniques (anterior segment OCT or Scheimpflug camera). The first treatment modality, 
which is usually simplest, if the cornea is clear, is peripheral laser iridotomy. This is usually 
performed with Neodymium: Yttrium-Aluminum-Garnet (Nd:YAG) laser. After instillation 
of topical pilocarpine 2% or 4% and topical analgesic (e.g., oxybuprocaine HCl 0.4% or 
proparacaine HCl 0.5%) eye drop, a spot of 10mJ is placed over the peripheral iris. Two 
pulses may be used simultaneously. The size of the spot is constant depending on the 
instrument (50-70μm). The spot is placed at the periphery of the iris in the superior half to 
avoid glare and over a thin part of the iris (usually a crypt) avoiding blood vessels. If 
bleeding occurs, the cornea is pressed by a contact lens until bleeding ceases. The procedure 
may be performed with contact lens such as Abraham (+66D), Wise (+103D), CGI or without 
it. The advantages of a contact lens are additional magnification, focusing the beam, 
absorbing part of the heat, stabilizing the eye and maintaining the eyelids open. Topical 
glycerin may be placed over the cornea before the procedure if it is edematous. Topical 
apraclonidine (Iopidine®) 0.5%-1.0% or other alpha 2 agonist (e.g., brimonidine tartrate) is 
administered following the procedure to decrease IOP spikes and corticosteroids such as 
prednisolone acetate 1% qid are prescribed of a week to decrease intraocular inflammation 
and risk for synechiae formation. Additional anti-glaucoma medications may be added. This 
procedure facilitates aqueous flow from the posterior into the anterior chamber and may 
result in deepening of the anterior chamber and lowering the IOP. The major complication is 
acceleration of cataract. If Nd:YAG laser is unavailable, Argon laser iridotomy may be 
performed. The parameters for this procedure depend on the iris pigmentation. For brighter 
iris, the power is lower than for darker ones. The preparatory stretch burns are of 200-
600mW, 0.2-0.6 sec, 200-500μm. The penetration burns are of 800-1000mW, 0.2 sec, 50μm. 
The iridotomy size should be increased to 150-500μm. The position of the Argon iridotomy 
in this case is preferably supero-nasal to prevent injury to the macula. The treatment before 
and after the procedure is identical to Nd:YAG laser iridotomy. Perforation of the iris is 
obtained when aqueous mixed with pigment is flowing from the posterior to the anterior 
chamber through the iridotomy. The lens should be visible through the iridotomy, since 
positive transillumination is not reliable. When laser iridotomy is not feasible, surgical 
peripheral iridectomy should be performed. Complications include visual disturbances such 
as halo and glare, development and progression of cataract, corneal burns that are usually 
transient, temporary increase in IOP, intraocular inflammation and rarely retinal injury, 
CME and malignant glaucoma. 
If laser iridotomy does not result in decrease in IOP, surgical peripheral goniosynechiolysis 
or laser peripheral iridoplasty may be performed. This should be performed as earlier as 
possible and preferably if the angle closure is of less than 6 months. Otherwise, it is usually 
useless, because of scarring. Peripheral goniosynechiolysis is performed through a 
paracentesis. It may be performed under viscoelastic material or with anterior chamber 
maintainer. A spatula is transferred along the peripheral iris to withdraw it from the angle. 
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Goniosynechiolysis may be performed in a similar way with viscoelastic agent injected 
toward the angle to open it. However, the viscoelastic material should be removed at the 
conclusion of the procedure to prevent postoperative high IOP. Laser iridoplasty is 
performed after instillation of topical anesthetic eye drop with Argon laser, 200-400mW, 0.3-
0.6 sec, 500 μm, 20-40 burns in a row with 2-beam diameter space between each spot over 
360˚ peripheral iris avoiding blood vessels. The procedure is performed with a contact lens 
such as the Abraham (+66D), Wise (+103D), CGI or Goldmann three-mirror lens (through 
the center, non-mirror part) or without it. The preparations before and the management 
following the procedure are similar to this described above for Nd:YAG laser iridotomy. 
The procedure is aimed to contract the peripheral iris away from the angle. The 
contraindications for the procedure include extensive synechial closure and flat anterior 
chamber. The complications of the procedure include corneal burns, increased IOP, iritis, 
new synechiae formation and mydriasis. 
If the IOP did not decrease substantially to the target level following these two procedures, 
medical treatment with anti-glaucoma medications including pilocarpine 2% four times a 
day may be added. If pilocarpine is added, it is worthwhile to have two consecutive days off 
this medication every month. This decreases the probability to have fixed small pupil, which 
may be an obstacle if cataract extraction is required. 
If the IOP remained high or becoming high despite of medical treatment, other surgical 
procedures may be performed. The usual approach is to have trabeculectomy first. 
Trabeculectomy in this case may require a long tunnel (or sclerostomy) that will penetrate 
the peripheral cornea anterior to the peripheral anterior synechiae.    
When a trabeculectomy is failed, a glaucoma shunt tube may be placed as mentioned earlier. 
In aphakic and pseudophakic eyes it may be placed into the ciliary sulcus. 
11. Steroid-induced glaucoma 
Steroid-induced glaucoma is defined as elevation of IOP following administration of topical 
and/or systemic corticosteroids that remains high after their discontinuation. Steroid 
responder is a patient in whom the IOP returns to normal after discontinuation of the 
steroids. These medications are often used after corneal transplantation to prevent or treat 
corneal graft rejection. They are also used to treat postoperative intraocular inflammation. 
Differentiation between steroid-induced glaucoma and inflammatory (uveitic) glaucoma 
may be performed by increasing the topical corticosteroid dosage for several days. If IOP 
remains high despite decreased intraocular inflammation, a corticosteroid-induced 
glaucoma is most reasonable. 
In cases of steroid responders or steroid-induced glaucoma, discontinuation of the 
corticosteroids is mandatory. Patients, who are steroid responders, should be aware that 
they are "allergic" to steroid in the specific form that causes their IOP to increase. This 
should be written in their medical chart and added to a note (or a card) for the patient, 
specify that he should not receive this type of drug. For episodes of graft immune rejection, 
a combination of topical NSAID (sodium diclofenac 0.1% or ketorolac tromethamine 0.5%) 
and topical cyclosporine-A may be employed. Systemic cyclosporine-A or other drugs such 
as PO tacrolimus 0.1mg/kg/day may be added. Another option is to use IOP-sparing 
corticosteroids such as loteprednol etabonate 0.5% (Lotemax®) or rimexolone 1% (Vexol®). 
Judicious use of systemic corticosteroids instead of topical corticosteroids may be adopted if 
they do not cause an increase in IOP. 
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The treatment of steroid-induced glaucoma follows the same principles applied for primary 
open-angle glaucoma (see above). 
12. Glaucoma in patients with corneal and posterior segment disorders  
Glaucoma in cases of posterior segment disorders (e.g. proliferative diabetic retinopathy, 
neovascular glaucoma, uveitic glaucoma) along with corneal disorders are more challenging 
to treat. Pars plana vitrectomy may require a temporary keratoprosthesis for visualization of 
the posterior segment. Following which, a corneal transplantation is being performed. 
Otherwise, pars plana vitrectomy may be performed endoscopically. In both instances, if the 
glaucoma is refractory to medical treatment, a pars plana implantation of glaucoma 
drainage implant is advised.  
Cyclodestructive procedures should be avoided if possible, because the degree of IOP 
reduction and intraocular inflammation are unpredictable. Excessive intraocular 
inflammation may cause intense pain, CME and hypotony that may result in phthisis bulbi. 
External inflammation may cause excessive scarring of the conjunctiva, preventing other 
procedures such as trabeculectomy to be performed. The corneal graft may also fail. 
Cyclodestructive procedures should be reserved only for painful eyes with no potential for 
visual rehabilitation. If cyclodestructive procedures are employed, transscleral 
cyclophotocoagulation (contact or non-contact, Nd:YAG or diode laser) or transcorneal 
ciliary processes photocoagulation should be preferred over cyclocryoablation. The former 
causes less postoperative pain, postoperative inflammatory reaction and phthisis bulbi than 
cyclocryoablation. Even when transscleral cyclophotocoagulation (contact or non-contact, 
Nd:YAG or diode laser) or transcorneal ciliary processes photocoagulation is being 
performed, it may be applied to half to two thirds of the ciliary body to prevent these 
complications. This book contains a chapter on controlled cyclophotocoagulation to decrease 
complications. 
For cyclodestructive procedures, sub-Tenon, peribulbar or retrobulbar anesthesia with 2% 
lidocaine (or a 1:1 mixture with 0.75% bupivicaine) is used. Transscleral Nd:YAG (1064nm) 
may be contact or non-contact, continuous or pulsed. Eight to 25 applications of 1.5-10J are 
placed 2-3mm beyond the limbus over 180°. This position corresponds to the location of the 
ciliary body and is confirmed by transillumination. Trans scleral Diode (810nm), 10-20 
applications of 5-6mJ over 180-270° is performed 2mm posterior to the limbus. Following the 
procedure, topical corticosteroids such as prednisolone acetate 1% qid or more and atropine 
sulfate 1% tid for a few weeks are warranted. Analgesia may also be required. The anti-
glaucoma medications are tapered gradually according to the decrease in IOP. The success 
of the procedure is usually assessed 4 weeks after treatment. The complications include 
hyphema, corneal decompensation, chronic intraocular inflammation, CME, epiretinal 
membranes, chronic hypotony and even phthisis bulbi. They may be fewer with Diode laser 
with G-probe.33 
13. Prognosis 
The prognosis of preexisting glaucoma depends on its type.17 It is usually more favorable for 
primary open angle glaucoma as long as precautions have been taken during the 
penetrating keratoplasty or the lamellar grafting. The prognosis for graft survival is also 
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better than with other types of preexisting glaucoma, as long as the IOP is well controlled 
and the corneal graft has a healthy endothelium. 
The prognosis for secondary open angle glaucoma is similar. If the IOP is poorly controlled, 
there are increased risks for corneal decompensation and development of bullous 
keratopathy that may require additional grafting. However, performing corneal 
transplantation in an eye with uncontrolled glaucoma is inadvisable. Resolution of post-
keratoplasty glaucoma has been observed in chronic angle closure glaucoma after an 
additional corneal transplantation probably due to changes in the angle configuration by 
applying the above advises. In steroid responders, the IOP returns to normal following 
discontinuation of the corticosteroids.  
With the approaches described in this chapter, it would be possible to improve the outcomes 
of patients with corneal transplants and coexisting glaucoma. 
13.1 Follow-up 
Patients undergoing corneal surgery and having or developing glaucoma usually have 
concurrent disorders and are more challenging to treat. These patients should be followed-
up regularly at least every 3 months for their lifetime. If they experience ocular pain, 
decrease in vision or redness of the eye, they should immediately report to their 
ophthalmologist. It is essential not to postpone the next step in treatment if the current one 
is not sufficient to abolish the risk of further deterioration.  
14. Controversies in management of glaucoma in patients with corneal grafts 
Whether trabeculectomy with MMC or glaucoma drainage implant is the surgical treatment 
of choice for glaucoma in patients with corneal grafts is still controversial. Different authors 
have reported comparable results with both. At present, it is up to the decision of the 
surgeon according to his experience. Comparative studies are required for a definite answer. 
Such studies will be required also to decide whether simultaneous procedures have the 
same success rate as separate procedures and whether the new anterior glaucoma devices 
such as Solx gold shunt or iStent, will have a benefit over the posterior ones. 
15. Glaucoma in cases of permanent keratoprosthesis 
Several types of keratoprosthesis are available including one that pass through the cornea 
and fused eyelids (type II) and the more common ones through the cornea only (type I, e.g., 
Boston and osteo-odonto-keratoprosthesis) (Figures 6,7). Keratoprosthesis is usually reserved 
for eyes in which other corneal procedures have failed and the prognosis for additional ones 
is poor. A publication on repeated corneal transplantation demonstrated that as the number 
of repeated corneal grafts is increased, the prognosis for long-term survival of the regraft 
decreases.12 Most of the regrafts do fail due to graft rejection, glaucoma and other 
complications. These findings have led keratoprosthesis specialists to advocate 
keratoprosthesis. However, the publication was intended to elaborate the importance of 
proper preventive measures and early and correct treatment of corneal transplantation 
complications of rather than to advocate the use of keratoprosthesis. With better preventive 
measures and treatments, it will be possible to decrease the necessity for repeated 
transplantation and of course to avoid keratoprosthesis.  
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Fig. 6. Type I keratoprosthesis (courtesy of Peter Rubin, MD) 
 
 
Fig. 7. Type II keratoprosthesis (courtesy of Peter Rubin, MD) 
Many of the patients undergoing keratoprosthesis have multiple ocular pathologies and 
glaucoma is one of them. Between 36-76% of the eyes with keratoprosthesis have 
glaucoma.34-39 Of these, about 2-28% develop glaucoma after the implantation of 
keratoprosthesis, usually because of progressive angle closure. This may be caused because 
of inadvertent injury to the angle and postoperative intraocular inflammation. A peripheral 
iridectomy may decrease the risk of postoperative angle closure. The prosthesis may also 
serve as a scaffold for retoprosthetic membrane that may cover the angle. The use of 
corticosteroids for prolonged period may also cause corticosteroid-induced glaucoma in 
susceptible patients.  
Glaucoma is more frequent in keratopsrosthetic patients than in repeated corneal 
transplantation. One of the most challenging situations in the presence of keratoprosthesis is 
to detect and follow-up glaucoma, because it is impossible to check the IOP using the 
standard methods such as Goldmann applanation tonometry or Schiotz indentation 
tonometry. These instruments are employed through normal cornea and not through a 
keratoprosthesis, which cannot be indent. In many cases, visualization of the optic disc may 
be difficult and therefore, changes in cupping are difficult to observe or document directly, 
or indirectly using Heidelberg Retinal Tomography (HRT), scanning laser polarimeter 
(GDx) or OCT. Reliable visual fields may also be difficult to obtain and the maximal field 
that may be obtained is 60° with type I and 40° with type II. 
It is paramount to obtain the history of glaucoma in patients with keratoprosthesis and to 
document it. In presence of keratoprosthesis, IOP qualitative estimation may be performed 
by digital palpation over the sclera. It should not be performed over the keratoprosthesis or 
the glaucoma shunt plate. Qualitative estimation with glass rod over the conjunctiva is  
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Fig. 8. The tip of Ahmed shunt tube seen through type I keratoprosthesis. It was placed into 
the vitreous though the pars plana (courtesy of Peter Rubin, MD) 
 
 
Fig. 9. A modified Ahmed closed shunt (courtesy of Peter Rubin, MD) 
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more challenging as quantitative estimation of the IOP by Tonopen or Schiotz indentation 
tonometry through the limbal area. If the IOP cannot be estimated in follow-up visits, it is 
also possible to follow patients by observing the optic disc and visual fields for deterioration 
as is done with some patients without keratoprosthesis who do not allow checking their 
IOP. New transducers are being developed to allow IOP measurements in patients with 
keratoprosthesis. 
In patients who are candidate for keratoprosthesis, it is preferable to implant glaucoma 
drainage device and to wait for 3-6 months before placing the keratoprosthesis especially 
when the IOP is refractory to medical treatment or the damage to the optic disc is advanced.  
This period would allow the postoperative intraocular inflammation to subside and to the 
IOP to stabilized.  
The respond to medical treatment in patients with keratoprosthesis is limited because there 
is no absorption area in patients with type II and limited absorption area with type I 
keratoprosthesis and the glaucoma is usually more severe compared with glaucoma in 
penetrating keratoplasty. The next step is introducing a glaucoma drainage device 
(Figure 8). A placement of glaucoma shunt tube into the vitreous through the pars plana 
may be better than into the anterior chamber that is already crowded because of the back-
plate of the prosthesis. In aphakic eyes, it is mandatory to ascertain that no vitreous remains 
in the anterior chamber, by meticulous anterior vitrectomy. Since the patients are either 
aphakic or pseudophakic, the tube may be inserted through the ciliary sulcus. Recently, it 
was suggested to place the valved drainage tube such as Ahmed valve in the lacrimal sac, 
ethmoid or maxillary sinuses and to avoid the subconjunctival plate.38,39 The shunt tube was 
modified for this purpose (Figure 9) and was placed into the lacrimal sac or the ethmoid 
sinus through an external dacryocystorhinostomy incision although it may be placed in a 
similar manner as a Pyrex tube in conjunctivo-dacryo-cystorhinostomy. Placement into the 
maxillary sinus was performed through a lower eyelid crease or subciliary incision but it is 
also possible to go through the inferior fornix. Penetration may be performed with 
intravenous catheter and the tube may be passed through it after removing the catheter hub. 
These procedures may decrease the failure of glaucoma shunt tube from fibrosis around the 
subconjunctival plate. The main risk in these cases is endophthalmitis. Therefore, I would 
not advocate these procedures if the lacrimal sac or the sinus is not sterile. Therefore, such a 
procedure should be avoided in patients with active sinusitis or history of this disorder. In 
one series of 37 patients, one (3%) developed endophthalmitis.38 Cyclophotocoagulation 
may be employed as an adjunct treatment to glaucoma drainage implants for painful eyes 
with no potential for visual rehabilitation.42,43 
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